Sinopharm Group CoSHTDY -0.97%73 Return-on-Tangible-Equity is 10.26% as of Dec. 2025, which is 40% below its 10-year median of 17.03. GuruFocus rates SHTDY with a GF Score™ of 73/100 and a GF Value™ of $13.05 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 111 Medical Distribution companies, Sinopharm Group Co ranks better than 57.66% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sinopharm Group Co's annualized net income for the quarter that ended in Dec. 2025 was $1,048 Mil. Sinopharm Group Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $10,212 Mil. Therefore, Sinopharm Group Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 10.26%.
The historical rank and industry rank for Sinopharm Group Co's Return-on-Tangible-Equity or its related term are showing as below:
SHTDY'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.16 Med: 17.03 Max: 20.2
Current: 10.16
During the past 13 years, Sinopharm Group Co's highest Return-on-Tangible-Equity was 20.20%. The lowest was 10.16%. And the median was 17.03%.
SHTDY's Return-on-Tangible-Equity is ranked better than 57.66% of 111
companies
in the Medical Distribution industry
Industry Median: 9.07
vs SHTDY: 10.16
Sinopharm Group Co (OTCPK:SHTDY) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sinopharm Group Co Return-on-Tangible-Equity Related Terms
Sinopharm Group Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co Return-on-Tangible-Equity Chart
SHTDY vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Sinopharm Group Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.26% mean?
Sinopharm Group Co (SHTDY) has a Return-on-Tangible-Equity of 10.26% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sinopharm Group Co and its competitors. This is 40% below median its historical median of 17.03. Over the past decade, Sinopharm Group Co's Return-on-Tangible-Equity has ranged from 10.16 to 20.20. According to the industry distribution chart, Sinopharm Group Co ranks #47 out of 111 companies in the Medical Distribution industry, placing it in the top 42.3%.
Is Sinopharm Group Co's Return-on-Tangible-Equity too high?
Sinopharm Group Co's current Return-on-Tangible-Equity of 10.26% is 40% below median its 10-year median of 17.03. Over the past 10 years, this metric has ranged from a low of 10.16 to a high of 20.20. The Medical Distribution industry median Return-on-Tangible-Equity is 9.07. Sinopharm Group Co's value of 10.26% is 13.1% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #47 out of 111 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #47 out of 111 companies for Return-on-Tangible-Equity. This puts Sinopharm Group Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 9.07. Sinopharm Group Co's value of 10.26% is 13.1% above this benchmark. Historically, Sinopharm Group Co's own Return-on-Tangible-Equity has ranged from 10.16 to 20.20 over the past decade. While the company's 10-year median is 17.03 vs. the industry median of 9.07, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 9.07, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Return-on-Tangible-Equity of 10.26% is 13.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 9.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Return-on-Tangible-Equity is 10.26%, which is 40% below median its own 10-year median of 17.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $10.16 — trading 22.1% below its estimated fair value. The current Return-on-Tangible-Equity is 10.26%, which is 40% below median its 10-year median of 17.03 and 13.1% above the Medical Distribution industry median of 9.07. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Return-on-Tangible-Equity is 10.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDY) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $10.16 is trading 22.1% below its estimated GF Value™ of $13.05.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDY:
Return-on-Tangible-Equity: 10.26% (40% below median its 10-year median of 17.03)
GF Value™: $13.05 vs. price of $10.16 (22.1% below fair value)
Industry Position: 13.1% above the Medical Distribution median (#47 of 111)
No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score
Get the complete analysis for SHTDY
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDY has been successfully added to your 
